HC Wainwright Has Optimistic Outlook of ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – HC Wainwright boosted their FY2025 EPS estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, January 13th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will earn ($0.15) per share for the year, up from their previous estimate of ($0.42). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q4 2025 earnings at $0.02 EPS, FY2026 earnings at $0.58 EPS and FY2027 earnings at $0.81 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.07). The business had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million.

A number of other brokerages also recently commented on ESPR. Cantor Fitzgerald restated an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Wall Street Zen upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 3rd. Piper Sandler assumed coverage on Esperion Therapeutics in a research note on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Wednesday, October 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.20.

Esperion Therapeutics Trading Down 2.1%

Shares of NASDAQ:ESPR opened at $3.23 on Thursday. Esperion Therapeutics has a 1 year low of $0.69 and a 1 year high of $4.18. The business has a fifty day simple moving average of $3.56 and a 200 day simple moving average of $2.65. The firm has a market cap of $772.16 million, a price-to-earnings ratio of -6.46, a P/E/G ratio of 10.11 and a beta of 1.04.

Insider Activity at Esperion Therapeutics

In related news, CFO Benjamin Halladay sold 7,337 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total value of $26,926.79. Following the transaction, the chief financial officer directly owned 467,525 shares of the company’s stock, valued at approximately $1,715,816.75. This trade represents a 1.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On Esperion Therapeutics

A number of large investors have recently added to or reduced their stakes in ESPR. Two Seas Capital LP grew its holdings in Esperion Therapeutics by 43.6% during the second quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after purchasing an additional 3,024,104 shares during the last quarter. AIGH Capital Management LLC bought a new stake in shares of Esperion Therapeutics during the 3rd quarter worth $7,950,000. Royce & Associates LP acquired a new position in Esperion Therapeutics in the 3rd quarter valued at $6,078,000. Marshall Wace LLP raised its holdings in Esperion Therapeutics by 46.2% in the 2nd quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock worth $5,206,000 after acquiring an additional 1,679,294 shares during the period. Finally, Integral Health Asset Management LLC bought a new position in Esperion Therapeutics in the 3rd quarter worth $3,975,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.